Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Three China-Based Biopharmas Receive US De-listing Notices

publication date: Mar 11, 2022

The US Securities and Exchange Committee warned three China biopharmas that their US-listed ADRs face delisting in three years time. The three companies, Beigene, Zai Lab and Hutchmed, were singled out because they have filed their 2021 annual reports to US regulators. Last year, the US passed a law requiring US-listed companies to submit their financial reports to a US auditor. That's a problem because China prohibits its companies from letting a foreign group audit their finances. The company have three years to solve the problem or they will be de-listed. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital